FDA Class II Recall D-0086-2026, initiated July 30, 2025, for BPC-157/Thymosin Beta-4 injectable presentations (10/10mg, 15/15mg, 15mg/15mg); reason: lack of assurance of sterility; distributed nationwide.
Testing and trust
Third-party COA
No
Reputation
Community trust
Compromised due to active FDA Class II recall for sterility failures in reconstitution products.
Reported issues
- •Tirzepatide product failed sterility assurance testing
- •Class II recall indicates potential serious health risk
Reported issues describe what our data shows. They are not a legal finding.
Contact
For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.